Patent ID: 8603482
Filing Date: 2013-12-10
Classification: A61K,A61P

Abstract:
1. A method for stimulating an immune response to a cancer antigen in a subject individual, the method comprising the steps of: administering to the individual one or more anti-cancer antibodies generated against said cancer antigen; and administering to the individual a compound of formula (I) wherein: R a and b are each independently 0, 1, 2, 3 or 4; a′ and b′ are independently 2, 3, 4, 5, 6, 7 or 8; d and e are each independently 1, 2, 3, 4, 5 or 6; d′ and e′ are each independently 0, 1, 2, 3 or 4; d″ and e″ are each independently 0, 1, 2, 3 or 4; T is oxygen or sulfur; X W R R R G or G Z R M is independently selected from a hydrogen atom and a pharmaceutically acceptable cation; and/or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, amorphous solid thereof, or any combination thereof; wherein the one or more anti-cancer antibodies is selected from the group consisting of trastuzumab, bevacizumab, rituximab, pertuzumab, cetuximab, IMC-1C11, tositumomab, ibirtumomab tiuxetan, EMD 7200, SGN-30, SGN-15, SGN-40, SGN-35, and SGN-17/19, and the compound of formula (I) is ER 804057 and/or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or amorphous solid thereof.